Figure 11: Effects of simvastatin allocation on site-specific cancers subdivided by age and total cholesterol at study entry

<table>
<thead>
<tr>
<th>Cancer site by age (years) &amp; total cholesterol (mmol/L)</th>
<th>Simvastatin -allocated (10,269)</th>
<th>Placebo -allocated (10,267)</th>
<th>Event rate ratio (95% CI)</th>
<th>Heterogeneity p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;70</td>
<td>101 (1.4%)</td>
<td>95 (1.3%)</td>
<td></td>
<td>p=1.0</td>
</tr>
<tr>
<td>≥70</td>
<td>78 (2.7%)</td>
<td>72 (2.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chol &lt;5.0</td>
<td>36 (1.8%)</td>
<td>35 (1.7%)</td>
<td></td>
<td>p=0.9</td>
</tr>
<tr>
<td>≥5.0</td>
<td>143 (1.7%)</td>
<td>132 (1.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any respiratory</td>
<td>179 (1.7%)</td>
<td>167 (1.6%)</td>
<td>1.06 (0.86 - 1.31)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;70</td>
<td>145 (2.0%)</td>
<td>131 (1.8%)</td>
<td></td>
<td>p=0.2</td>
</tr>
<tr>
<td>≥70</td>
<td>83 (2.8%)</td>
<td>92 (3.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chol &lt;5.0</td>
<td>51 (2.5%)</td>
<td>62 (3.0%)</td>
<td></td>
<td>p=0.2</td>
</tr>
<tr>
<td>≥5.0</td>
<td>177 (2.1%)</td>
<td>161 (2.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any gastrointestinal</td>
<td>228 (2.2%)</td>
<td>223 (2.2%)</td>
<td>1.01 (0.84 - 1.22)</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;70</td>
<td>138 (1.9%)</td>
<td>156 (2.1%)</td>
<td></td>
<td>p=0.4</td>
</tr>
<tr>
<td>≥70</td>
<td>121 (4.1%)</td>
<td>116 (4.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chol &lt;5.0</td>
<td>52 (2.6%)</td>
<td>65 (3.2%)</td>
<td></td>
<td>p=0.3</td>
</tr>
<tr>
<td>≥5.0</td>
<td>207 (2.5%)</td>
<td>207 (2.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any genitourinary</td>
<td>259 (2.5%)</td>
<td>272 (2.6%)</td>
<td>0.94 (0.80 - 1.12)</td>
<td></td>
</tr>
<tr>
<td>All others</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;70</td>
<td>101 (1.4%)</td>
<td>109 (1.5%)</td>
<td></td>
<td>p=0.3</td>
</tr>
<tr>
<td>≥70</td>
<td>73 (2.5%)</td>
<td>61 (2.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chol &lt;5.0</td>
<td>38 (1.9%)</td>
<td>44 (2.2%)</td>
<td></td>
<td>p=0.4</td>
</tr>
<tr>
<td>≥5.0</td>
<td>136 (1.7%)</td>
<td>126 (1.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any other</td>
<td>174 (1.7%)</td>
<td>170 (1.7%)</td>
<td>1.01 (0.82 - 1.25)</td>
<td></td>
</tr>
<tr>
<td>ALL CANCERS (except non-melanoma skin)</td>
<td>814 (7.9%)</td>
<td>803 (7.8%)</td>
<td>1.00 (0.91 - 1.11)</td>
<td></td>
</tr>
</tbody>
</table>